Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.44 |
| ▸ | CA9 | Q16790 | 3/20 | 0.44 |
| ▸ | GRIA1 | P42261 | 5/20 | 0.44 |
| ▸ | GRIA2 | P42262 | 5/20 | 0.44 |
| ▸ | GRIA3 | P42263 | 5/20 | 0.44 |
| ▸ | GRIA4 | P48058 | 5/20 | 0.44 |
| ▸ | GRIK1 | P39086 | 3/20 | 0.43 |
| ▸ | GRIK2 | Q13002 | 3/20 | 0.43 |
| ▸ | GRIK3 | Q13003 | 3/20 | 0.43 |
| ▸ | GRIK4 | Q16099 | 3/20 | 0.43 |
| ▸ | GRIK5 | Q16478 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2597175 | 0.90 | GRIA1 (0.43) | CA12CA9GRIA1GRIA2GRIA3 | |
| SCHEMBL2597384 | 0.86 | GRIA1 (0.46) | CA12CA9GRIA1GRIA2GRIA3 | |
| SCHEMBL2597151 | 0.86 | GRIA1 (0.45) | CA12CA9GRIA1GRIA2GRIA3 | |
| SCHEMBL2597214 | 0.84 | GRIA1 (0.42) | CA12CA9GRIA1GRIA2GRIA3 | |
| SCHEMBL2597153 | 0.79 | DDR1 (0.35) | CA12CA9 | |
| SCHEMBL2597401 | 0.77 | CA12 (0.48) | CA12CA9GRIA1GRIA2GRIA3 | |
| SCHEMBL2597191 | 0.77 | GRIA1 (0.51) | CA12CA9GRIA1GRIA2GRIA3 | |
| SCHEMBL2597177 | 0.77 | LIPG (0.35) | CA12CA9 | |
| SCHEMBL2597227 | 0.76 | CFTR (0.46) | CA12CA9 | |
| SCHEMBL2597306 | 0.76 | CFTR (0.46) | CA12CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2571865-A1 | 2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL-SULFONAMIDE DERIVATIVES | Novartis AG (CH) | 2013-03-27 | — | — | EP | claimed |
| US-20130053381-A1 | 2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL-SULFONAMIDE DERIVATIVES | NOVARTIS AG | 2013-02-28 | — | — | US | claimed |
| WO-2011144666-A1 | 2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL-SULFONAMIDE DERIVATIVES | NOVARTIS AG (CH) | 2011-11-24 | — | — | WO | claimed |
| EP-2571865-A1 | 2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL-SULFONAMIDE DERIVATIVES | Novartis AG (CH) | 2013-03-27 | — | — | EP | disclosed |
| US-20130053381-A1 | 2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL-SULFONAMIDE DERIVATIVES | NOVARTIS AG | 2013-02-28 | — | — | US | disclosed |
| US-20130053381-A1 | 2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL-SULFONAMIDE DERIVATIVES | NOVARTIS AG | 2013-02-28 | — | — | US | disclosed |
| US-20130053381-A1 | 2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL-SULFONAMIDE DERIVATIVES | NOVARTIS AG | 2013-02-28 | — | — | US | disclosed |
| WO-2011144666-A1 | 2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL-SULFONAMIDE DERIVATIVES | NOVARTIS AG (CH) | 2011-11-24 | — | — | WO | disclosed |
| WO-2011144666-A1 | 2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL-SULFONAMIDE DERIVATIVES | NOVARTIS AG (CH) | 2011-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130053381-A1 | 2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL-SULFONAMIDE DERIVATIVES | GRIK2, GRIK1, GRIK4 | CA12 1465/4885CA9 2087/4885GRIA1 40/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.